Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we’ll get caught up with highlights from the annual meeting of The European Society for Medical Oncology, which has been underway in Berlin. We’re seeing the onward march of ADCs into earlier cancers, particularly breast.
Unexpected regulatory updates from Replimune, Summit Therapeutics
From STAT’s Adam Feuerstein: Let’s start with Replimune, which said this morning the Food and Drug Administration will review RP1, its therapy for advanced melanoma, for a second time, based on a resubmission that included additional data and analysis from a completed clinical trial. The new approval decision date is April 10.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
